news
GCD enables product traceability and batch definition in continuous biomanufacturing
Research shows using the greatest common divisor (GCD) to define batches in continuous biomanufacturing enhances process control and raw material traceability.
List view / Grid view
Therapeutics
news
Intranasal anti-depressant drug successfully delivered to the brain
A new pre-clinical study succeeded in the intranasal delivery of an anti-depressant peptide-based drug to the brain in mouse models.
news
Cosentyx®displays a 72 percent reduced arthritis flare risk
Cosentyx® resulted in a 72 percent reduced flare risk for enthesitis-related arthritis and juvenile psoriatic arthritis in a Phase III study.
news
Depression drug shows positive results in groundbreaking Phase IIb study
COMP360 25mg versus 1mg comparator dose demonstrated a -6.6 point difference on the Montgomery-Åsberg Depression Rating Scale by week 3.
news
Aimovig®displays superiority over topiramate in migraine study
Amgen announces positive results from the first and only randomised, double-blind, head-to-head study comparing Aimovig® to topiramate.
podcasts
EPR Podcast Episode 5 – ATMP manufacturing and QC – Rey Mali, Accellix and Félix Montero-Julian, bioMérieux
Join Rey Mali and Félix Montero-Julian as they discuss the challenges facing the manufacture and QC of advanced therapy medicinal products (ATMPs) and potential solutions.
news
Rinvoq® shows positive results in rheumatoid arthritis post-hoc analysis
In the analysis, 34 percent of rheumatoid arthritis patients receiving Rinvoq® achieved Clinical Disease Activity Index (CDAI) remission.
news
Wegovy™ demonstrates sustained weight loss in two-year obesity study
Novo Nordisk's Wegovy™ reduced body weight by 15.2 percent versus 2.6 percent with placebo in Phase IIIb study.
news
Anti-viral COVID-19 nasal spray to be commercialised
Birmingham Biotech and the University of Birmingham, UK, have signed a licensing agreement for an anti-viral nasal spray against COVID-19.
news
Oral antiviral candidate Paxlovid™ reduces COVID-19 risks by 89 percent
Paxlovid™, Pfizer's investigational oral antiviral candidate, displayed an 89 percent reduction in COVID-19 risks in Phase II/III study.
news
NICE recommend dapagliflozin for treating chronic kidney disease
The new draft guidance has recommended dapagliflozin as an option for treating certain people with chronic kidney disease (CKD) in adults.
news
Gates biomanufacturing facility announces agreement with Nkarta
The Gates Biomanufacturing Facility announced a strategic agreement with Nkarta to manufacture Nkarta's investigational cell therapy NKX101.
news
Actimab-A CLAG-M combination displays 100 percent remission rate
Actinium's Actimab-A CLAG-M combination showed a 100 percent remission rate in relapsed or refractory acute myeloid leukaemia patients receiving 0.75 μCi/kg in Phase I study.
article
Developing and delivering live biotherapeutic products
The microbial content of the gut has a well established role in health and disease. In this article, European Pharmaceutical Review’s Hannah Balfour explores the development and formulation of live biotherapeutic products (LBPs), an emerging treatment modality that seeks to capitalise on the interaction between the microbiota and host in…
news
Biktarvy® shows high efficacy against HIV in real-world setting
Gilead's Biktarvy demonstrated a consistently high efficacy of over 95 percent in analyses of the ongoing real-world cohort BICSTaR study.
